In vitro activity of sulbactam-durlobactam against colistin-resistant and/or cefiderocol-non-susceptible, carbapenem-resistant Acinetobacter baumannii collected in U.S. hospitals.
Publication
, Journal Article
Iovleva, A; McElheny, CL; Fowler, EL; Cober, E; Herc, ES; Arias, CA; Hill, C; Baum, K; Fowler, VG; Chambers, HF; Greenwood-Quaintance, KE ...
Published in: Antimicrob Agents Chemother
March 6, 2024
The activity of a novel β-lactamase inhibitor combination, sulbactam-durlobactam (SUL-DUR), was tested against 87 colistin-resistant and/or cefiderocol-non-susceptible carbapenem-resistant Acinetobacter baumannii clinical isolates collected from U.S. hospitals between 2017 and 2019. Among them, 89% and 97% were susceptible to SUL-DUR and imipenem plus SUL-DUR, with MIC50/MIC90 values of 2 µg/mL/8 µg/mL and 1 µg/mL/4 µg/mL, respectively. The presence of amino acid substitutions in penicillin-binding protein 3, including previously reported A515V or T526S, was associated with SUL-DUR non-susceptibility.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Antimicrob Agents Chemother
DOI
EISSN
1098-6596
Publication Date
March 6, 2024
Volume
68
Issue
3
Start / End Page
e0125823
Location
United States
Related Subject Headings
- Sulbactam
- Microbiology
- Microbial Sensitivity Tests
- Imipenem
- Humans
- Hospitals
- Drug Combinations
- Colistin
- Cefiderocol
- Azabicyclo Compounds
Citation
APA
Chicago
ICMJE
MLA
NLM
Iovleva, A., McElheny, C. L., Fowler, E. L., Cober, E., Herc, E. S., Arias, C. A., … Doi, Y. (2024). In vitro activity of sulbactam-durlobactam against colistin-resistant and/or cefiderocol-non-susceptible, carbapenem-resistant Acinetobacter baumannii collected in U.S. hospitals. Antimicrob Agents Chemother, 68(3), e0125823. https://doi.org/10.1128/aac.01258-23
Iovleva, Alina, Christi L. McElheny, Erin L. Fowler, Eric Cober, Erica S. Herc, Cesar A. Arias, Carol Hill, et al. “In vitro activity of sulbactam-durlobactam against colistin-resistant and/or cefiderocol-non-susceptible, carbapenem-resistant Acinetobacter baumannii collected in U.S. hospitals.” Antimicrob Agents Chemother 68, no. 3 (March 6, 2024): e0125823. https://doi.org/10.1128/aac.01258-23.
Iovleva A, McElheny CL, Fowler EL, Cober E, Herc ES, Arias CA, et al. In vitro activity of sulbactam-durlobactam against colistin-resistant and/or cefiderocol-non-susceptible, carbapenem-resistant Acinetobacter baumannii collected in U.S. hospitals. Antimicrob Agents Chemother. 2024 Mar 6;68(3):e0125823.
Iovleva, Alina, et al. “In vitro activity of sulbactam-durlobactam against colistin-resistant and/or cefiderocol-non-susceptible, carbapenem-resistant Acinetobacter baumannii collected in U.S. hospitals.” Antimicrob Agents Chemother, vol. 68, no. 3, Mar. 2024, p. e0125823. Pubmed, doi:10.1128/aac.01258-23.
Iovleva A, McElheny CL, Fowler EL, Cober E, Herc ES, Arias CA, Hill C, Baum K, Fowler VG, Chambers HF, Greenwood-Quaintance KE, Patel R, van Duin D, Bonomo RA, Doi Y. In vitro activity of sulbactam-durlobactam against colistin-resistant and/or cefiderocol-non-susceptible, carbapenem-resistant Acinetobacter baumannii collected in U.S. hospitals. Antimicrob Agents Chemother. 2024 Mar 6;68(3):e0125823.
Published In
Antimicrob Agents Chemother
DOI
EISSN
1098-6596
Publication Date
March 6, 2024
Volume
68
Issue
3
Start / End Page
e0125823
Location
United States
Related Subject Headings
- Sulbactam
- Microbiology
- Microbial Sensitivity Tests
- Imipenem
- Humans
- Hospitals
- Drug Combinations
- Colistin
- Cefiderocol
- Azabicyclo Compounds